Skip to main content
Figure 1 | Critical Care

Figure 1

From: Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy

Figure 1

Simulated plasma SBECD pharmacokinetic profiles in all subjects. Data represent 1,000 patient simulations for SBECD exposure with voriconazole 6 mg/kg IV every 12 hours for two doses followed by 4 mg/kg IV every 12 hours from time 0 to day 7. Data presented as mean concentration (solid line) and standard deviation (dashed lines). SBECD, sulfobutylether-β-cyclodextrin; IV, intravenous.

Back to article page

Critical Care

ISSN: 1364-8535